ResultsIQ

ResultsIQ › Latest results › Marksans Pharma Limited

Marksans Pharma Limited Q3 FY26 results press release summary

NSE: MARKSANS · BSE: 524404

Results press release of 5 Feb 2026, summarised by AI from the filing.

Marksans Q3 FY26 operating revenue ₹754.4 cr, up 10.6% YoY, with EBITDA margin at 21.3%, expanded 217 bps YoY.

Key takeaways

  1. Q3 revenue Operating revenue ₹754.4 cr, up 10.6% YoY, on traction in US and UK markets and new product launches.
  2. Q3 EBITDA EBITDA ₹160.7 cr with margin 21.3%, expanded 217 bps YoY.
  3. Margin drivers Margins expanded on soft raw material costs, favorable currency movements and an improving product mix.

Original filing on BSE

Marksans Pharma Limited Q1 FY27 results

As filed: Revenue ₹841 cr (+36% year on year), EBITDA ₹213 cr (+113% year on year), PAT ₹159 cr (+175% year on year), EBITDA margin 25.3% (+921 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹856 cr (+300% year on year), EBITDA ₹195 cr (+300% year on year), PAT ₹149 cr (+300% year on year), EBITDA margin 22.8% (+593 bps). Score 100 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 593 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +20.1% in 30 days (Nifty 500: +3.3%).
  • Q3 FY26: Revenue ₹754 cr (+11% year on year), EBITDA ₹161 cr (+16% year on year), PAT ₹114 cr (+8% year on year), EBITDA margin 21.3% (+93 bps). Score 57 of 100, In line with trend. Revenue, EBITDA and profit growth were in line with the company's own trend. EBITDA margin rose 93 bps year on year. Share price after the results: +2.4% in 29 days (Nifty 500: +1.7%).
  • Q2 FY26: Revenue ₹720 cr (+12% year on year), EBITDA ₹144 cr (+5% year on year), PAT ₹99.0 cr (+1% year on year), EBITDA margin 20.0% (−134 bps). Score 52 of 100, In line with trend. Revenue, EBITDA and profit growth were in line with the company's own trend. EBITDA margin fell 134 bps year on year. Share price after the results: +2.5% in 28 days (Nifty 500: +0.4%).
  • Q1 FY26: Revenue ₹620 cr (+5% year on year), EBITDA ₹100 cr (−22% year on year), PAT ₹58.0 cr (−35% year on year), EBITDA margin 16.1% (−553 bps). Score 43 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 553 bps year on year. Consolidated profit -35% but standalone +50%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −17.1% in 30 days (Nifty 500: +2.1%).
  • Q4 FY25: Revenue ₹71.0 cr (−87% year on year), EBITDA ₹12.0 cr (−89% year on year), PAT ₹9.0 cr (−88% year on year), EBITDA margin 16.9% (−256 bps). Score 0 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 256 bps year on year. Consolidated profit -88% but standalone +15%. Revenue fell 90% from last quarter. Revenue rose ₹-489.0 cr on a year ago, against ₹74.0 cr the year before. Share price after the results: −1.3% in 30 days (Nifty 500: +0.3%).
  • Q3 FY25: Revenue ₹682 cr (+16% year on year), EBITDA ₹139 cr (+5% year on year), PAT ₹105 cr (+27% year on year), EBITDA margin 20.4% (−232 bps). Score 44 of 100, In line with trend. Revenue and EBITDA growth were below the company's own trend; profit growth was above it. EBITDA margin fell 232 bps year on year. Revenue rose ₹96.0 cr on a year ago, against ₹106 cr the year before.
  • Q2 FY25: Revenue ₹642 cr (+21% year on year), EBITDA ₹137 cr (+19% year on year), PAT ₹98.0 cr (+17% year on year), EBITDA margin 21.3% (−32 bps). Score 61 of 100, In line with trend. EBITDA margin fell 32 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Marksans Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.